AbbVie (ABBV) Net Cash Flow (QoQ) (2012 - 2026)
AbbVie (ABBV) Net Cash Flow (QoQ) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1,115.57% |
| Dec 31, 2025 | 50.48% |
| Sep 30, 2025 | -165.77% |
| Jun 30, 2025 | 452.51% |
| Mar 31, 2025 | 78.78% |
| Dec 31, 2024 | 71.31% |
| Sep 30, 2024 | -19.34% |
| Jun 30, 2024 | -193.49% |
| Mar 31, 2024 | 1,162.70% |
| Dec 31, 2023 | -110.92% |
| Sep 30, 2023 | 120.80% |
| Jun 30, 2023 | 182.39% |
| Mar 31, 2023 | 5.88% |
| Dec 31, 2022 | -178.75% |
| Sep 30, 2022 | 37.21% |
| Jun 30, 2022 | 167.20% |
| Mar 31, 2022 | -51.79% |
| Dec 31, 2021 | -165.49% |
| Sep 30, 2021 | 397.49% |
| Jun 30, 2021 | -190.82% |